[go: up one dir, main page]

WO2000030669A3 - Use of plasma phospholipid transfer proteins in treating cardiovascular dieases - Google Patents

Use of plasma phospholipid transfer proteins in treating cardiovascular dieases Download PDF

Info

Publication number
WO2000030669A3
WO2000030669A3 PCT/NL1999/000720 NL9900720W WO0030669A3 WO 2000030669 A3 WO2000030669 A3 WO 2000030669A3 NL 9900720 W NL9900720 W NL 9900720W WO 0030669 A3 WO0030669 A3 WO 0030669A3
Authority
WO
WIPO (PCT)
Prior art keywords
dieases
phospholipid transfer
treating cardiovascular
plasma phospholipid
transfer proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL1999/000720
Other languages
French (fr)
Other versions
WO2000030669A2 (en
Inventor
Crom Marinus Petrus Gerardu De
Gent Teunis Van
Haperen Marinus Johannes Van
Tol Arie Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus Universiteit Rotterdam
Original Assignee
Erasmus Universiteit Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus Universiteit Rotterdam filed Critical Erasmus Universiteit Rotterdam
Priority to AU14168/00A priority Critical patent/AU1416800A/en
Publication of WO2000030669A2 publication Critical patent/WO2000030669A2/en
Publication of WO2000030669A3 publication Critical patent/WO2000030669A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the field of cardiovascular diseases, in particular to the field of diseases associated with elevated plasma levels of cholesterol and/or triglycerides in mammals, particularly in man. The present inventors have found beneficial pharmaceutical effects of plasma phospholipid transfer protein (PLTP) and have shown that it is feasible to make pharmaceutical compositions for the treatment of cardiovarcular disorders based on PLTP.
PCT/NL1999/000720 1998-11-24 1999-11-23 Use of plasma phospholipid transfer proteins in treating cardiovascular dieases Ceased WO2000030669A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14168/00A AU1416800A (en) 1998-11-24 1999-11-23 Use of plasma phospholipid transfer proteins in treating cardiovascular dieases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203962 1998-11-24
EP98203962.0 1998-11-24

Publications (2)

Publication Number Publication Date
WO2000030669A2 WO2000030669A2 (en) 2000-06-02
WO2000030669A3 true WO2000030669A3 (en) 2000-10-19

Family

ID=8234379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1999/000720 Ceased WO2000030669A2 (en) 1998-11-24 1999-11-23 Use of plasma phospholipid transfer proteins in treating cardiovascular dieases

Country Status (2)

Country Link
AU (1) AU1416800A (en)
WO (1) WO2000030669A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018227A1 (en) * 1993-12-30 1995-07-06 Zymogenetics, Inc. Phospholipid transfer proteins
WO1995034289A1 (en) * 1994-06-14 1995-12-21 The Rockefeller University Compositions for neutralization of lipopolysaccharides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018227A1 (en) * 1993-12-30 1995-07-06 Zymogenetics, Inc. Phospholipid transfer proteins
WO1995034289A1 (en) * 1994-06-14 1995-12-21 The Rockefeller University Compositions for neutralization of lipopolysaccharides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. FÖGER ET AL.: "PLASMA PHOSPHOLIPID TRANSFER PROTEIN.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 43, 24 October 1997 (1997-10-24), MD US, pages 27393 - 27400, XP002109523 *
J.J. ALBERS ET AL.: "TRANSGENIC MICE EXPRESSING HUMAN PHOSPHOLIPID TRANSFER PROTEIN HAVE INCREASED HDL/non-HDL CHOLESTEROL RATIO.", INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, vol. 26, no. 4, December 1996 (1996-12-01), HEIDELBERG, DE, pages 262 - 267, XP002109521 *
R. VAN HAPEREN ET AL.: "HUMAN PLASMA PHOSPHOLIPID TRANSFER PROTEIN INCREASES THE ANTIATHEROGENIC POTENTIAL OF HIGH DENSITY LIPOPROTEINS IN TRANSGENIC MICE.", ARTHERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 20, no. 4, April 2000 (2000-04-01), DALLAS, TX, US, pages 1082 - 1088, XP000915014 *
X.-C. JIANG ET AL.: "INCREASED PRE-BETA-HIGH DENSITY LIPOPROTEIN, APOLIPOPROTEIN AI, AND PHOSPHOLIPID IN MICE EXPRESSING THE HUMAN PHOSPHOLIPID TRANSFER PROTEIN AND HUMAN APOLIPOPROTEIN AI TRANSGENES.", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 10, 15 November 1996 (1996-11-15), NEW YORK, N.Y., US, pages 2373 - 2380, XP002109522 *

Also Published As

Publication number Publication date
AU1416800A (en) 2000-06-13
WO2000030669A2 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
WO2004019884A3 (en) Agents and methods for enhancing bone formation
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
BR9807673A (en) Processes to treat allergic asthma and dermatitis in a human and pharmaceutical composition.
WO2003009704A3 (en) Enteral compositions for the prevention and/or treatment of sepsis
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
ZA947529B (en) Inhibitors of beta-amyloid protein production
ZA966798B (en) Methods of reducing or maintaining reduced levels of blood lipids using OB protein compositions.
NO20063328L (en) Use of a fatty acid composition comprising at least one of EPA and DHA or combinations thereof
HK1044543B (en) Beta-secretase enzyme compositions and methods
AU4835693A (en) Pharmaceutical composition comprising phosphatase or a derivative thereof
EP0797999A3 (en) Formulations of obesity protein
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
ATE355057T1 (en) USE OF AROMATIC OR BRANCHED AMINO ACIDS TO TREAT MOVEMENT DISORDERS
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
WO1996013498A3 (en) L-erythrosyl nucleosides
WO2000030669A3 (en) Use of plasma phospholipid transfer proteins in treating cardiovascular dieases
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
WO2003092701A3 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
PT782630E (en) GENE OF THE POLITICAL DISEASE OF RIM
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
WO1999055859A3 (en) Cd40-interacting and traf-interacting proteins
WO2002083700A3 (en) Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
AU2010792A (en) Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
NO951762D0 (en) Stable preparation for the treatment of blood coagulation disorders, comprising an active coagulation promoter

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 14168

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase